Laboratory Corporation of America Holdings (LH) Stock

Laboratory Corporation of America Holdings operates as a global leader in the life sciences sector, delivering essential information that supports informed decisions for doctors, hospitals, pharmaceutical companies, researchers, and patients worldwide. The company operates through two main segments: Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Its extensive range of diagnostic tests includes blood chemistry analyses, urinalyses, thyroid tests, PAP tests, genetic and esoteric testing, and specialized tests targeting diseases such as oncology, cardiovascular conditions, and infectious diseases.

In addition to diagnostic services, Laboratory Corporation of America provides comprehensive occupational testing, medical drug monitoring, chronic disease management programs, and advanced solutions for kidney stone prevention. The company leverages online and mobile applications to empower patients to access and manage their test results efficiently, while also offering managed care organizations and accountable care organizations digital tools to streamline healthcare management.

Furthermore, Laboratory Corporation of America offers end-to-end solutions in drug development, medical device testing, and companion diagnostic development. These services span from early-stage research through clinical trials to commercial market access, serving a diverse clientele that includes managed care organizations, pharmaceutical and biotechnology firms, medical device manufacturers, government agencies, healthcare providers, and patients. Founded in 1994 and headquartered in Burlington, North Carolina, the company continues to innovate and expand its capabilities to meet the evolving needs of the healthcare and life sciences industries.